{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-039151","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.277643+00:00","generated_at":"2026-06-03T00:57:12.017311+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"60 Degrees Pharma gets FDA comments on tafenoquine babesiosis trial; no material changes needed","bullets":["FDA provided comments on the clinical trial protocol for tafenoquine in treating babesiosis on April 26, 2024.","No material changes to trial design required; company will address FDA questions and recommendations.","Preparatory actions continue; patient enrollment expected to begin later in 2024.","Tafenoquine is FDA-approved for malaria prophylaxis as ARAKODA but not yet for babesiosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-039151","json":"https://secwatch.observer/filing/0001213900-24-039151.json","markdown":"https://secwatch.observer/filing/0001213900-24-039151.md","text":"https://secwatch.observer/filing/0001213900-24-039151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024039151/0001213900-24-039151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024039151/ea0205181-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:57:12.017311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}